J9395 Fulvestrant - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Fulvestrant

Brand Name:

Faslodex

Strength:

25 mg

HCPCS:

J9395

SEER*Rx Category:

Hormonal Therapy

Major Drug Class:

Estrogen Receptor Antagonist

Minor Drug Class:

Oral (Y/N):

No

FDA Approval Year:

2002

FDA Discontinuation Year:

CMS Effective Date:

Jan. 1, 2004

CMS Discontinuation Date:

Status:

In Use